BCR and prostate cancer: Current tools have limited capacity to identify, at time of RP, men that are most at risk of metastasis and prostate cancer death - such patients are currently treated aggressively only after the observation of rising PSA (Prostate Specific Antigen) or biochemical recurrence (BCR).